Sulforaphane ameliorates glucose intolerance in obese mice via the upregulation of the insulin signaling pathway

Yan Xu; Jian-Fei Fu; Jia-Hui Chen; Zhuang-Wei Zhang; Zu-Quan Zou; Li-Yuan Han; Qi-Hang Hua; Jin-Shun Zhao; Xiao-Hong Zhang; Yu-Juan Shan

doi:10.1039/c8fo00763b

journal article Jan 01, 2018

Sulforaphane ameliorates glucose intolerance in obese mice via the upregulation of the insulin signaling pathway

Yan Xu

Jian-Fei Fu Jia-Hui Chen Zhuang-Wei Zhang Zu-Quan Zou Li-Yuan Han Qi-Hang Hua Jin-Shun Zhao

Xiao-Hong Zhang

Yu-Juan Shan

Food & Function Vol. 9 No. 9 pp. 4695-4701 · Royal Society of Chemistry (RSC)

View at Publisher Save 10.1039/c8fo00763b

Abstract

Sulforaphane (SFN) is a dietary component with multiple bioactivities; however, its role in obesity-related metabolic derangement remains unclear.

Topics

No keywords indexed for this article. Browse by subject →

References

28

[1]

G. A. Bray and C.Bouchard , Handbook of obesity : clinical applications , Book , 2014 , p. 680 10.1201/b16473

[2]

Care Natl. Inst. Health Clin. Excellence (2006)

[3]

Myzak Cancer Lett. (2006) 10.1016/j.canlet.2005.02.033

[4]

Thimmulappa Cancer Res. (2002)

[5]

Dinkova-Kostova Proc. Natl. Acad. Sci. U. S. A. (2002) 10.1073/pnas.172398899

[6]

Fahey Food Chem. Toxicol. (1999) 10.1016/s0278-6915(99)00082-4

[7]

Lenzi Mutat Res. (2007) 10.1016/j.mrrev.2006.10.004

[8]

Bahadoran Diabetes Res. Clin. Pract. (2012) 10.1016/j.diabres.2012.01.009

[9]

Bahadoran Int. J. Food Sci. Nutr. (2012) 10.3109/09637486.2012.665043

[10]

Choi J. Nutr. Biochem. (2014) 10.1016/j.jnutbio.2013.10.007

[11]

de Souza J. Med. Food (2012) 10.1089/jmf.2012.0016

[12]

Lee Biochem. Biophys. Res. Commun. (2012) 10.1016/j.bbrc.2012.08.107

[13]

Axelsson Sci. Transl. Med. (2017) 10.1126/scitranslmed.aah4477

[14]

Kahn Nature (2006) 10.1038/nature05482

[15]

Briones-Herrera Food Funct. (2018) 10.1039/c8fo00018b

[16]

Defronzo J. Clin. Invest. (1985) 10.1172/jci111938

[17]

Taylor Cell (1999) 10.1016/s0092-8674(00)80709-6

[18]

Giorgino J. Clin. Invest. (1993) 10.1172/jci116424

[19]

Taniguchi J. Clin. Invest. (2005) 10.1172/jci23187

[20]

Araki Nature (1994) 10.1038/372186a0

[21]

Tamemoto Nature (1994) 10.1038/372182a0

[22]

Yamauchi Mol. Cell. Biol. (1996) 10.1128/mcb.16.6.3074

[23]

Saltiel Nature (2001) 10.1038/414799a

[24]

Kahn J. Clin. Invest. (1991) 10.1172/jci115254

[25]

Lee Diabetes Res. Clin. Pract. (2007) 10.1016/j.diabres.2007.01.033

[26]

Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance

Ariel Zisman, Odile D. Peroni, E. Dale Abel et al.

Nature Medicine 2000 10.1038/78693

[27]

Tremblay Diabetes (2001) 10.2337/diabetes.50.8.1901

[28]

Postic J. Clin. Invest. (2008) 10.1172/jci34275

Metrics

38

Citations

28

References

Details

Published: Jan 01, 2018
Vol/Issue: 9(9)
Pages: 4695-4701
License: View

Authors

Y

Yan Xu